The email may take a few minutes to arrive

If it’s not in your inbox, please check your spam folder 

If you’re having trouble, please email: support@ada.com

Please leave this window open and check back after you’ve verified your email address. A verification email was sent to:

The email may take a few minutes to arrive.

If you can’t see it, check your spam folder.

If you still can’t find it, please email support@ada.com.

Reset instructions have been sent to [EMAIL]

Please enter the email you signed up with, and we will send you a password reset link

To continue, please sign up for an Ada account. If you have used the Ada app, you already have an Ada account.

Please sign in with the option you originally signed up with.

Please enter your email address and choose a secure password to create your Ada account.

I consent to any personal health data I voluntarily provide here being used by Ada to create (3.2) and personalise (3.3) my account, as well as provide health assessments and guidance (3.5).

I agree to Ada’s Terms & Conditions and confirm that I am at least 16 years old.

Please read our Privacy Policy and confirm the following declarations. Consents can be withdrawn at any time.

China’s 8 most popular symptom checkers showed a range of coverage, safety, and accuracy, factors relevant to user and physician choice.

Ada offered the highest coverage (99.5%) and advice safety (99.5%) compared with the average (69.6% and 90.3%, respectively).

Ada’s accuracy was significantly higher, and more than twice the average (61.5% vs 28.7%).

Breadth of coverage and accuracy of Chinese language digital symptom assessment apps for suggesting conditions and urgency advice: A clinical vignettes evaluation

Ada was significantly more accurate in the recognition of inflammatory rheumatic diseases (IRD) than physicians (70% vs physicians' 54%), which included experienced rheumatology physicians.

Ada was more accurate than physicians in suggesting the correct final diagnosis (54% of cases vs physicians' 32%).

Highlights the potential of using symptom checkers early in the patient journey and the advantages of considering complete patient information to establish a correct diagnosis.

Shows the potential of symptom checkers to make accurate triage and diagnostic decisions in rheumatology.

Comparison of physician and artificial intelligence-based symptom checker diagnostic accuracy

Ada outperformed all other symptom checkers in suggesting the correct diagnosis for skin rashes.

Ada's top condition suggestion matched the correct diagnosis in 73.3% of cases, vs an average of 30.8%.

The correct diagnosis was provided within Ada's top three condition suggestions in 93.3% of instances vs an average of 43.3%.

Online symptom checkers lack diagnostic accuracy for skin rashes

Real-world hospital ED study of 378 patients, comparing the safety of Ada’s urgency advice to that of the Manchester Triage System (MTS). 

Ada demonstrated a high rate of safety (94.7%) over all medical specialties of the Emergency Department, with a focus on Internal Medicine, Orthopedics and Trauma, and Neurology.

From the 3 lowest MTS categories, 43.4% could have safely accessed lower urgency care such as seeing a GP or managing their symptoms at home.

Ada has the potential to relieve pressure on Emergency Departments by guiding patients to lower urgency care if used at home.

Safety of Triage Self-Assessment Using a Symptom Assessment App for Walk-in Patients in the Emergency Care Setting: Observational Prospective Cross-sectional Study

One of Ada's top 5 condition suggestions matched therapist's formal diagnoses in 69% of cases, and Ada's top suggestion matched in 51% of cases.

Symptom checkers have potential to complement the mental health diagnostic process, but further investigation is recommended.

The usability of Ada was rated as high in the System Usability Scale.

Diagnostic Performance of an App-Based Symptom Checker in Mental Disorders: Comparative Study in Psychotherapy Outpatients

When used in combination with ER physicians assessments, Ada significantly increased diagnostic accuracy (87.3%) compared with an ER physician alone (80.9%).

Patients with early diagnosis and rapid treatment allocation exhibited significantly reduced complications and length of hospital stay. 

AI tools have the potential to benefit the diagnostic efficacy of clinicians and improve quality of care.

The Diagnostic Efficacy of an App-based Diagnostic Health Care Application in the Emergency Room: eRadaR-Trial. A Prospective, Double-Blinded, Observational Study

Ada’s DDSS prototype could support doctors’ decision-making by showing them new pathways and potential diagnoses.

Ada provided accurate decision support in the clinical inpatient setting for people presenting with dyspnea.

Prospective Feasibility Study of a Novel Diagnostic Decision Support System (DDSS) for Medical Professionals

Using a dataset from 464,547 patients, Ada's CVD risk prediction tool achieved superior performance to several established general CVD risk prediction models.

Ada could be used to direct individuals to app-based behavior change recommendations for risk reduction and guidance.

Actionable absolute risk prediction of atherosclerotic cardiovascular disease: a behavior-management approach based on data from 464,547 UK Biobank participants

Ada identified the correct condition in the top 3 suggestions in 83% of cases, compared to the next best of 77%, including Australia-specific scenarios.

63% of Ada’s urgency advice matched the gold standard, compared to the next highest app’s score of 52%

The quality of condition suggestions and urgency advice provided by the Ada symptom assessment app assessed with independently generated vignettes optimized for Australia

Ada had 73% accuracy compared to a 38% all-app average.

Ada's exhibited 97% disposition safety compared to an 83% all-app average.

Accuracy of online symptom checkers and the potential impact on service utilisation

The utility of symptom checkers relies on safety, coverage, and accuracy.

Ada’s advice was safe in 97% of cases, on par with GPs and with 99% condition coverage for the clinical scenarios.

Ada showed 70% accuracy for top 3 suggestion fit vs competitor average of 38%.

How accurate are digital symptom assessment apps for suggesting conditions and urgency advice?: A clinical vignettes comparison to GPs

46.4% of 26,646 Ada assessments were completed outside primary care clinic hours. 

Ada’s recommendations were comparable to triage nurses’.

Use Characteristics and Triage Acuity of a Digital Symptom Checker in a Large Integrated Health System: Population-Based Descriptive Study

Ada could help identify mental health disorders in adults.

Accuracy of a chatbot (Ada) in the diagnosis of mental disorders: Comparative case study with lay and expert users

Ada ranked highly on precision out of the 24 tested in the ear, nose, and throat (ENT) discipline.

From symptom to diagnosis-symptom checkers re-evaluated : Are symptom checkers finally sufficient and accurate to use? An update from the ENT perspective

Ada was the most accurate of the 4 apps tested.

Ada was found to be fast and easy to use.

What happened when Pulse tested symptom checker apps

Ada was "by far the best" app out of the 4 tested, asking clear questions and providing the best condition suggestions.

Can you really trust the medical apps on your phone?

Ada supported conversation and improved rapport for 90% of patients, 73% of physicians, and 100% of nurses. 

Patients reported high usability and understood the tool’s questions.

Improving emergency department patient-doctor conversation through an artificial intelligence symptom taking tool: an action-oriented design pilot study.

Ada could decrease the average triage nurse waiting times by 54%.

Optimization of Patient Flow in Urgent Care Centers Using a Digital Tool for Recording Patient Symptoms and History: Simulation Study

97.8% of patients rated Ada very or quite easy to use.

12.8% or patients would have delayed their appointment or used lower-intensity care.

Patients’ utilization and perception of an artificial intelligence-based symptom assessment and advice technology in a British primary care waiting room: Exploratory pilot study

Protocol for a clinical study set in a Tanzanian district hospital outpatient clinic to investigate the usefulness of a prototype diagnosis decision support system (DDSS) in the hands of a mid-level healthcare worker.

The diagnostic accuracy and qualitative data on the usability, usefulness, and acceptance of the prototype DDSS will provide insights on the appropriateness of the prototype DDSS interface.

Investigating the Potential for Clinical Decision Support in Sub-Saharan Africa With AFYA (Artificial Intelligence-Based Assessment of Health Symptoms in Tanzania): Protocol for a Prospective, Observational Pilot Study

The readability of Ada's consumer-facing medical text was reduced from grade 11, to grade 7 without compromising on medical quality.

AI companies can reduce the burden on vulnerable healthcare systems, but should be designed and adapted to the needs of the local population. 

Efforts should be made to reduce bias in AI by using white-box systems. 

Addressing the Challenges of Adapting an AI-Powered Symptom Assessment and Care Navigation Tool for South African Users

Protocol for first-of-type clinical study set in a Tanzanian district hospital outpatient clinic to investigate the usefulness of symptom assessment applications in LMICs.  

Evaluation of Ada's compared to gold-standard differential diagnoses and triage advice for participants with various conditions and age groups, including children. 

Study protocol for a pilot prospective, observational study investigating the condition suggestion and urgency advice accuracy of a symptom assessment app in Sub-Saharan Africa: the AFYA-'Health' study

AI solutions can only improve health outcomes in LMICs if they are designed and adapted with the needs of the local population in mind.

To account for regional differences in incidence and disease presentation, 51 maternal and pediatric health conditions were optimized in Ada for South Africa.

Ada’s content readability score has been reduced from grade 11 to below grade 8 (7.4±0.8) while still maintaining medical accuracy.

White-box AI-approach like Ada’s makes it possible to capture the differences in underrepresented populations and low-income countriea.

Challenges and solutions in adapting an AI-powered health management tool for South Africa

Ada could help detect genetic auto-inflammatory disorders, including the important group of Periodic Fever Syndromes.

What is confirmed in the diagnostics of autoinflammatory fever diseases? (German text)

Retrospective analysis of the diagnostic costs of rare inflammatory systemic diseases and the impact of a prototype Ada as a diagnostic decision support system (DDSS).  

If this Ada DDSS prototype were released, it has the potential to lead to earlier diagnosis and could save between 50% and 70% of diagnostic costs. 

Health economic benefits through the use of diagnostic support systems and expert knowledge

Ada suggested rare diseases in 4% of 15 million assessments, in line with the population rates.

Poster: Just how rare are rare diseases on Ada, a medical symptom checker?

89.25% of Ada’s top suggestions matched the confirmed diagnosis

33.3% of participants could have received their rare disease diagnosis in the first documented clinical visit with Ada.

Can a decision support system accelerate rare disease diagnosis? Evaluating the potential impact of Ada DX in a retrospective study.

Ada uncovered similar ILI trends to an official German surveillance system and could help identify health trends in countries without population-based monitoring systems.

Novel methods in the surveillance of influenza-like illness (ILI): exploration of data from the symptom assessment app Ada, Germany observational case study

A review of data from 950,000 users found that Ada could help uncover the impact of public health policies like COVID-19 lockdown measures. 

Syndromic surveillance insights from a symptom assessment app before and during COVID-19 measures in Germany and the United Kingdom: Results from repeated cross-sectional analyses.

Digital symptom-based screening tools can substantially reduce the transmission of COVID-19.

Applications like Ada (combined with testing and self-isolation) could prevent an additional 8% of the population being infected.

The Potential of Digital Symptom-based Screening to Reduce the Transmission of SARS-CoV-2: A Modelling Study

Letter to the Editor on 'Comment on “Accuracy and usability of a diagnostic decision support system in the diagnosis of three representative rheumatic diseases: a randomized controlled trial among medical students'

Letter to the Editor on 'The quality of diagnosis and triage advice provided by free online symptom checkers and apps in Australia'

Proposals by the EU and FDA have set the regulatory groundwork for algorithm change protocols. The FDA proposals are detailed and actionable but are yet to be finalized. The EU has not yet detailed its plan. The authors recommended the EU set out an approach that is coordinated, actionable, and consultative.   

The public, manufacturers, and medical community should be engaged to inform requirements of algorithm change, with a focus on post market surveillance, RWP measurement, clinical evaluation, and labeling.

Algorithm change protocols in the regulation of adaptive machine learning-based medical devices

Letter to the editor on 'Do Dr. Google and Health Apps Have (Comparable) Side Effects? An Experimental Study'

Letter to the editor on 'Periodic Manual Algorithm Updates and Generalizability: A Developer’s Response. Comment on “Evaluation of Four Artificial Intelligence–Assisted Self-Diagnosis Apps on Three Diagnoses:
Two-Year Follow-Up Study”'

Ada could help detect genetic autoinflammatory disorders, including familial Mediterranean fever.

Rare diseases 2030: How augmented AI will support diagnosis and treatment of rare diseases in the future.

Objective and peer-reviewed research can raise the industry bar for quality, safety, and performance. Here's some research that looks at the performance and efficacy of Ada's technology.

Scroll through or navigate to a topic of interest below.

We use cookies in our website in order to help provide you with a user-friendly, secure, and effective website. By clicking ‘accept’, you consent to the use of all cookies. However, you may also visit the Cookie Settings at any time to provide controlled consent, and you can withdraw your consent there. Read our Cookie Policy and our Privacy Policy to learn more.

We use cookies in our website in order to help provide you with a user-friendly, secure, and effective website. You may visit the Cookie Settings at any time to withdraw your consent. Read our Privacy Policy to learn more.

Read our Cookie Policy and our Privacy Policy to learn more.

Marketing cookies are used to track visitors across websites. The intention is to target advertising and measure the effectiveness of our campaigns. Please consider opting-in.

Marketing

Necessary cookies are essential to provide you with our Services. It enables basic functions like page navigation and access to secure areas of the Services. You cannot opt-out of this.

Necessary

Statistic and performance cookies help website owners to understand how visitors interact with websites by collecting and reporting usage information. We recommend opting-in.

Statistics and performance

Cookie Settings

This website uses cookies. Read our Cookie Policy and our Privacy Policy to learn more.

COVID-19 Risk Severity and Treatment Eligibility

There are currently no items in your cart.
Find some.

This website meets the HONcode standard for trustworthy health information.

Objective research helps advance the industry and ensures Ada’s medical quality and performance withstands scrutiny.